Mankind Pharma Q4 Result 2025: Net Profit Falls 10.7% to Rs 420.8 Crore, Revenue Jumps 27%, EBITDA Rises 16.5%

Mankind Pharma, a notable company among the top 200 on the Bombay Stock Exchange (BSE) in the pharma sector, has had mixed performance this quarter. India's fourth-largest pharmaceutical company disclosed its performance figures for the fourth quarter (Q4), revealing a decrease in consolidated net profit by 11 percent from the previous year, although its revenue saw a significant jump of 27 percent.

Mankind Pharma Q4 Results 2025 Announced: Net Profit Drops, Revenue Up

Mankind Pharma recorded a 10.7% year-on-year drop in consolidated net profit at Rs 420.8 crore, compared to Rs 471.2 crore in the same period last year. Despite the profit decline, the company saw a significant 27.1% increase in revenue, reaching Rs 3,079.4 crore, driven by strong growth in chronic therapies, a solid performance in consumer healthcare, and the consolidation of the recently acquired Bharat Serums and Vaccines (BSV) business.

Mankind Pharma EBITDA For FY 2025: Notably, the company's EBITDA surged by 16.5 percent, increasing from Rs 586.3 crore to Rs 683.2 crore from previous year. However, the profit margins stood at 22.2 percent, a slight decrease from the 24.2 percent recorded a year earlier.

Rajeev Juneja, Vice Chairman and Managing Director (MD) of Mankind Pharma announced, "Q4 marks continued outperformance in chronic therapies, strong momentum in the consumer business, and successful BSV integration. This has been a transformative year, and we are laying the foundation for long-term sustainable growth."

Mankind Pharma Full-Year Performance 2025

For the full fiscal year FY25, Mankind Pharma reported a revenue of Rs 12,207 crore, marking a 19% increase from the previous year. Domestic sales contributed Rs 10,675 crore, while exports saw a sharp 88% growth, reaching Rs 1,532 crore. Adjusted EBITDA margins for the year stood at 25.9%.

The company continues to lead the Indian pharmaceutical market by prescription count for the eighth consecutive year. Its consumer healthcare brands, including Manforce, Gas-O-Fast, and HealthOK, also experienced double-digit growth.

Mankind Pharma: Bharat Serum and Vaccines

Mankind Pharma acquired Bharat Serums and Vaccines to expand its specialty offerings, particularly in gynaecology and super-specialty therapies. The company reported smooth progress in the integration process and is actively investing in research and development while working to scale up key brands under the BSV portfolio.

Mankind Pharma Share Price Ahead of Earnings Call

On May 21, shares of Mankind Pharma closed at Rs 2,530.00, down by Rs 19.20 or 0.75% from the previous day. The stock opened at Rs 2,532.10, hit an intraday high of Rs 2,570.90, and touched a low of Rs 2,516.10 during the session before settling slightly lower by the end of the day.